Tag Archives: cancer

Chinese Medicine and Cancer Treatment Effectiveness

3 Apr

Shirley Wang writes in today’s Wall Street Journal that “scientists studying a four herb combination discovered some 1,800 years ago by Chinese herbalists have found that the substance enhances the effectiveness of chemotherapy in patients with colon cancer.

Cancer Research Saves Lives

18 Apr

The AACR debuted at its annual conference today an informative video about the accomplishments and possibilities of cancer research. Check it out.

Susan Desmond-Hellmann Featured in the San Francisco Chronicle

11 Apr

UCSF’s Dr. Susan Desmond-Hellmann is profiled in the Sunday, April 11, 2010 issue of the San Francisco Chronicle. The story is featured on the front page.

Imagining What’s Possible for Patients

18 Mar

Dr. Susan Desmond-Hellmann explains her translational vision for
fighting cancer during her recent keynote address to UCSF’s breast oncology leaders. She describes 1997 to 2001 as oncology’s golden years. Rituxan, Herceptin and Gleevec debuted and changed the face of cancer treatments. Dr. Desmond-Hellmann believes that academia can today play a critical role in introducing “the platinum age” of cancer drug development.

“Cancer research is too slow, too expensive, too inefficient and too uncertain…we need to understand earlier and with greater confidence what the best ideas are,” she says. Read the full article here.

New Clinical Trial Enables Rapid Screening of Breast Cancer Drugs

17 Mar

UCSF Chancellor Susan Desmond-Hellmann discusses the future of oncology
drug development and adaptive clinical trial design and what it means
to patients in an interview with Pharma Strategy Blog’s Sally Church.  Here are excerpts from the post:

    “What’s really neat about the I-SPY trial is that Laura Esserman, the PI of the trial, is a breast cancer surgeon here at UCSF and has added so much value to the project because she sees patients early and has a unique opportunity to offer neoadjuvant therapy.
Patients are getting their primary therapy before they get surgery, so for imaging and biomarkers – either established or exploratory – it is a fantastic opportunity. The endpoint is pathological complete response, so you can see if the tumor has disappeared or not.”

    “It’s a fantastic rapid readout model so you can get answers much more quickly in a year, including pathological specimens, along with the answers from biomarkers and imaging, which are important.
The FDA has allowed a master IND agreement for this study, so it will be possible to move agents in and out of the trial quickly. So if agent A looks promising it can be advanced quickly and more patients put on it, but if agent B looks toxic, it can be discarded quickly. It’s not just a clinical trial but a experimental trial process that gives you a rapid readout of whether the agent works or not.”

    “The hope is that you won’t wasting time and money in phase III trials, but most importantly, patients experience on that molecule. If the answer is yes on I-SPY, you then have a biomarker hypothesis for that agent and can then do a more traditional phase III trial having increased your chances of success.”

via www.pharmastrategyblog.com

Read about the i-Spy 2 adaptive clinical trial which was launched on March 17 in Washington.

Watch the video from the Biomarkers Consortium press conference:

A Year of Drug Development Firsts?

30 Dec

CNBC’s Mike Huckman looks back at pharma’s biggest decade, and also looks ahead at    what’s to come in today’s segment “Big Pharma’s Big Decade.” UCSF’s Chancellor Dr. Susan  Desmond-Hellmann is featured in the program. Dr. Desmond-Hellmann who brought the world’s anti-cancer blockbuster drugs to market says what she’s “most proud of is that we changed the way people think about cancer.”

2010 could be a year of firsts– the first therapeutic vaccine for prostate cancer, first Lupus    drug, first once a week drug to treat diabetes, and  the first new flu vaccine technology since the 1950’s.

According to Dr. Desmond-Hellmann, “what is tremendous is how there is literally an explosion of biology – it should be a golden era.” She also believes that there could be a significant break-through in Alzheimer’s disease on the horizon. Drugs today just treat the symptoms but don’t slow the progression.

Dr. Desmond-Hellmann concludes by saying: “If there was a genuine breakthrough in Alzheimer’s we’re talking about the kinds of medicines that could be the biggest products in the world… bigger than Lipitor and Avastin… from a business perspective this could be huge.”

Watch the video here.

The Future of Drug Development

30 Dec

UCSF Chancellor Susan Desmond-Hellmann is featured in the CNBC's special "Biopharma: 10 Years in the Making." Watch the segment here:

http://plus.cnbc.com/rssvideosearch/action/player/id/1372930025/code/cnbcplayershare

UCSF’s Elizabeth Blackburn Wins Nobel Prize in Medicine

6 Oct

Today, UCSF’s Elizabeth Blackburn won the Nobel Prize in Medicine. Here’s the video from the press conference held in San Francisco:

I-Spy Trial Offers Key Insights Into Locally Advanced Breast Cancer

30 May

Dr. Laura Esserman, director of UCSF Helen Diller Family Comprehensive Cancer Center’s Breast Care Center is spearheading the development of a clinical trials model designed to accelerate and improve the efficiency with which experimental breast cancer therapies are assessed.  The strategy, which involves the use of molecular markers and MRI, utilizes “adaptive design,” in which drugs are assessed over the course of months – rather than decades – and the information used in real time to direct the course of a trial.

The series of studies are known as I-SPY (investigation of serial studies to predict therapeutic response with imaging and molecular analysis) and are being carried out  in patients with locally advanced i.e., aggressive – breast cancer. The goals of I-SPY  are to establish a clinical trials model that supports the identification of drugs targeting the molecular profiles of aggressive cancers, and to reduce the duration of the drug-assessment process from the current 15 to 20 years down to a few years.

Dr. Esserman’s team presents several findings at ASCO today.  One provocative finding shows that large, locally advanced forms of breast cancer often emerge between regular mammogram exams. These “interval” cancers present an important opportunity for doctors and patients to take advantage of neoadjuvant therapies in advance of surgery, with the hope they would be responsive. The other finding is that using molecular markers, UCSF researchers identified a subset of patients who do well regardless of how they respond to neoadjuvant treatment. They also identified a subset  with poor prognosis for whom response to neoadjuvant therapy is a good predictor of long term outcome.

Read the press release:
Continue reading

Obama Seeks a Cure for Cancer: Makes Historic Commitment to Health Care Reform

24 Feb

ph2009022404312

“The time to take charge of our future is here,” Obama proclaimed this evening in his first address to a joint session of Congress, where he outlined his agenda for rebuilding America. He focused on  three priorities– energy, health care and education. President Obama made a historic commitment to comprehensive health care reform and said that he will seek a cure for cancer.

Here are the health care highlights from today’s address:

Already, we’ve done more to advance the cause of health care reform in the last 30 days than we’ve done in the last decade. When it was days old, this Congress passed a law to provide and protect health insurance for 11 million American children whose parents work full-time.

Our recovery plan will invest in electronic health records and new technology that will reduce errors, bring down costs, ensure privacy, and save lives.

It will launch a new effort to conquer a disease that has touched the life of nearly every American, including me, by seeking a cure for cancer in our time.

And — and it makes the largest investment ever in preventive care, because that’s one of the best ways to keep our people healthy and our costs under control.

This budget builds on these reforms. It includes a historic commitment to comprehensive health care reform, a down payment on the principle that we must have quality, affordable health care for every American.

You can read the full transcript here.

Sources: Politico, CNN